Current Edition:
 
|
Table of Contents
Editor's Note
Neil Love, MD |
| |
 |
Neoadjuvant and adjuvant studies with trastuzumab |
| |
Trastuzumab in the treatment of metastatic breast cancer |
| |
Preliminary results of the ATAC trial |
| |
Concurrent chemotherapy and radiation therapy |
| |
Patient preferences for learning results of clinical trials |
| |
Evaluation of a PPAR gamma agonist for metastatic disease |
| |
The future of targeted systemic therapy |
| |
|
|
| Jack Cuzick, PhD |
|
Unblinding the ATAC trial data |
| |
Superior efficacy of anastrozole compared to tamoxifen in the ATAC trial |
| |
Favorable side effect profile of anastrozole |
| |
Continuation of the ATAC trial |
| |
Differentiation between aromatase inhibitors |
| |
Forthcoming adjuvant endocrine trials |
| |
IBIS II trial of anastrozole in high-risk women |
| |
|
|
| William Gradishar, MD |
|
Capecitabine/taxane combinations in metastatic breast cancer |
| |
Phase II trial of capecitabine/paclitaxel |
| |
Combination versus sequential single-agent therapy in advanced disease |
| |
Capecitabine as first-line therapy |
| |
Implications of the ATAC trial for clinical practice |
| |
Endocrine treatment strategies for premenopausal women |
| |
|
| David W Miles, MD |
|
|
Potential underestimation of the capecitabine/docetaxel survival advantage |
| |
Treatment after progression on single-agent docetaxel in the XT versus T trial |
| |
Toxicities associated with the capecitabine/docetaxel combination |
| |
Mechanism of action of capecitabine |
| |
Role of single-agent capecitabine |
| |
|
| |
|
|
|
|
